Compare D R Horton Inc (DHI) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs Recursion Pharmaceuticals Inc — how do they compare? D R Horton Inc trades at $151.45 (market cap $42.18B), while Recursion Pharmaceuticals Inc trades at $3.38 (market cap $1.81B). The key difference: D R Horton Inc is far larger — about 23.3× Recursion Pharmaceuticals Inc's market cap, and D R Horton Inc pays a 1.19% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| DHI | RXRX | |
|---|---|---|
Market Cap | $42.18B | $1.81B |
Sector | Consumer Cyclical | Health |
52-Week High | $184.04 | $6.79 |
52-Week Low | $132.53 | $2.84 |
Enterprise Value | $47.28B | $1.33B |
Dividend Yield | 1.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DHI trades at $146.66, down 2.93% on the day, amid a bearish technical signal. The stock has consistently beaten earnings estimates in recent quarters, including Q2 2026 EPS of $3.20 versus $3.02 expected. However, revenue and net income have trended lower from 2023 peaks, with 2025 revenue at $34.25B and net income at $3.59B. The company maintains a reasonable valuation with a P/E of 14.37 and recently declared a $0.45 dividend payable in August 2026.
The outlook is mixed; strong execution and cash returns support the stock, but lowered guidance and margin pressure from elevated mortgage rates pose headwinds. Analyst consensus is nearly evenly split between Buy and Hold, with a $153 price target suggesting modest upside. Key risks include persistent demand softness in housing and competitive disruption from new entrants like Boxabl.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
